IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

By sjmartinez • September 28, 2023

Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki KI, Jia J, Lencioni R. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022 Nov 28;12(3):238-250. doi: 10.1159/000528272. PMID: 37767068; PMCID: PMC10521324.

Tags: Atezolizumab, Barcelona Clinic Liver Cancer stage B, Bevacizumab, Hematology/Oncology, Publications, unresectable

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui[...]

Secondary Neuropathy From Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report

Young P, Kroloff M. Secondary Neuropathy From Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report. Cureus. 2025 Oct 21;17(10):e95064. doi:[...]

Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy

Duesberg MS, Schiller G. Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy. Cureus. 2025 Oct 21;17(10):e95112. doi: 10.7759/cureus.95112. PMID: 41281092;[...]